by Madaline Spencer and James Radke, PhD | May 23, 2023
Akram Khan, MD, FCCP, Associate Professor of Pulmonary, Allergy, and Critical Care Medicine at Oregon Health & Science University, talks about medical assistance in dying (MAiD) regarding late-stage neuromuscular disorders. Recently, the American College of...
by Madaline Spencer and James Radke, PhD | May 22, 2023
Marc Rothenberg, MD, of the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR), and Professor of Medicine at Cincinnati Children’s Hospital, gives an overview of the recent study showing removal of milk from the diet is as effective as stricter...
by Madaline Spencer and James Radke, PhD | May 18, 2023
Sindhu Ramchandren, MD, Global Clinical Leader at Janssen Pharmaceuticals, explains the pathophysiology of myasthenia gravis and the need for more targeted therapies. Myasthenia gravis is an autoimmune, neuromuscular disorder characterized by weakness of the...
by Madaline Spencer and James Radke, PhD | May 11, 2023
Christian Marsolais, Ph.D., Chief Medical Officer of Theratechnologies, discusses three studies presented at the American Association for Cancer Research (AACR) conference targeting SORT1-positive cancers. Sudocetaxel zendusortide (TH1902) is a proprietary...
by James Radke, PhD | May 10, 2023
The U.S. Food and Drug Administration (FDA) has approved pegunigalsidase alfa (Elfabrio), a plant-based enzyme replacement therapy with an initial half-life of 78.9 ± 10.3 hours, for the treatment of adult patients with Fabry disease. Fabry disease is a rare X-linked...
